Convatec Group (FRA:2CV) Quality Rank


FRA:2CV Convatec Group PLC FRA:2CV
77 GF Score
Price €2.52
GF Value €2.98
! 4 Warning Signs
View Full Analysis

What is Convatec Group Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Convatec Group Quality Rank Related Terms

FRA:2CV
77GF Score
Convatec Group PLC FRA:2CV
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Convatec Group (FRA:2CV) Overvalued in 2026?

Based on GuruFocus' analysis, Convatec Group stock appears to be undervalued. The current stock price of €2.52 is trading 15.4% below its estimated GF Value™ of €2.98.

Key valuation signals for FRA:2CV:

  • Quality Rank:
  • GF Value™: €2.98 vs. price of €2.52 (15.4% below fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the FRA:2CV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Convatec Group Business Description

Address 20 Eastbourne Terrace, 7th Floor, London, GBR, W2 6LG
Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 32% and 28% of total revenue, respectively. Continence care has become a slightly smaller business (22% of revenue) following the decision to exit the acute care market, and infusion sets contribute 18% of consolidated revenue.
77GF Score

Get the complete analysis for FRA:2CV

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.52
Price
€2.98
GF Value